

Supplementary Table 2. Cellular Therapies in Organ Injury Clinical Trials

Official Title	ClinicalTrials.gov Identifier	Status	Phase	Target Enrollment	Ages	Cell Type	Route of Administration	Primary Outcome Measure	Sponsor
A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome	NCT01775774	This study is currently recruiting participants.	I, II	69	18 Years and older	BMMSC	IV	Incidence of adverse events	Michael A. Matthay, USA
A Pilot Study for the Efficacy and Safety of Mesenchymal Stem Cell in Acute Severe Respiratory Failure	NCT02112500	This study is currently recruiting participants.	II	10	20 to 80 years	BMMSC (Lungcellgram)	IV	Oxygen index at 3 days after mesenchymal stem cell infusion	Asan Medical Center, South Korea
A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation Setting	NCT02175303	This study is currently recruiting participants.	I, II	25	N/A	PDSC	IV	Incidence of adverse events	Karolinska Institutet, Sweden
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects	NCT01602328	This study has been terminated.	II	156	21 years and older	MSC	N/A	Time to kidney recovery defined as a post-operative serum creatinine return to pre-operative baseline values	Allocure Inc., USA
Human Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Cerebral Hemorrhage	NCT02283879	This study is not yet open for participant recruitment.	I	20	40 to 80 years	UC-MSC	IV	Safety evaluation through vital signs, the results of clinical lab tests and adverse events (AEs)	Shenzhen Hornetcorn Biotechnology Company, LTD., China
Phase I Clinical Trial, Dose-escalating Intra-aortic Infusion of Allogeneic , Bone Marrow-derived Multipotent Stromal Cells to Prevent and Treat Post-operative Acute Kidney Injury in Patients Who Require On-pump Cardiac Surgery	NCT00733876	This study has been completed.	I	15	18 years and older	BMSiC	N/A	Incidence of adverse events	Allocure Inc., USA
Phase I Study of Allogeneic Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome	NCT01902082	This study is currently recruiting participants.	I	20	18 to 90 years	AdMSC	IV	Incidence of adverse events	Shaoxing Second Hospital, China
Phase I Study of Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells	NCT02277145	This study is currently recruiting participants.	I	14	18 to 70 years	UC-MSC	Injected via bronchoscopy after fully lavage of the localized lesions	Composite indicators, including quantitative analysis of CT density histograms, self-evaluation and changes of TGF- β 1 content	Jianwu Dai, China
Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome	NCT02097641	This study is currently recruiting participants.	II	60	18 years and older	BMMSC	IV	Incidence of adverse events within 6 hours of infusion, cardiac arrest or death within 24 hours of infusion, any adverse events	Michael A. Matthay, USA